Company intelligence / Profile preview
Aktis Oncology
Boston, Massachusetts, United Statesaktisoncology.com ↗
- Ownership
- Public · AKTS
- Employees
- ~41
- Development stage
- Clinical
01
Overview
Aktis Oncology's lead candidate AKY-1189, a Nectin-4 targeted radiopharmaceutical, has demonstrated substantial tumor uptake across several solid tumor types in early clinical data. The company is preparing to start a Phase 1 US study in Nectin-4-expressing tumors in 2025.
- Therapeutic areas
- Oncology
- Modalities
- Targeted alpha radiopharmaceuticalsMiniprotein radioconjugates
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Eli Lilly and Company
04
Financials
- Market cap
- $798.1M
- Total revenue
- $6.5M
- Enterprise value
- $292.1M
Beyond the preview
Go deeper on Aktis Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aktis Oncology.